![Page 1: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/1.jpg)
Why Idera Pharmaceuticals Soared 20% In September
![Page 2: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/2.jpg)
What:• The clinical-stage biotech company is studying two drugs.– IMO 8400 for B-cell lymphomas.– IMO 9200 for autoimmune disease.
• Data should be released on IMO 8400 in Q4.– Results from its phase 2 Waldenstrom’s
macroglobulinemia trial.• Shares jumped 20.1% in September.
![Page 3: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/3.jpg)
Idera Pharmaceuticals
![Page 4: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/4.jpg)
So what:• Under development to treat Waldenstrom’s and diffuse
B-cell lymphoma with an amenable genetic mutation.– Could benefit up to 90% of 1,200 new WM cases
annually.– Could treat up to 30% of the 2,000 new diffuse B-cell
lymphoma cases annually.
![Page 5: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/5.jpg)
Now what:
• WM phase 2 data coming this quarter.– Mid stage results could be encouraging, but a phase 3
trial still needs to occur.• Diffuse B-cell lymphoma data expected next year.– Potential therapy for pre-treated patients would be
welcome, but too early to gauge whether this one will be a success.
![Page 6: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/6.jpg)
Now what continued:
• Cash totals $106.3 million exiting Q2.– Operating expenses totaled $12.8 million last quarter.– Expanding trials will increase cash burn in the coming
year.• High-risk/high-reward play suitable only for aggressive
investors.– Keep an eye out for upcoming WM data.
![Page 7: Why Idera Pharmaceuticals Soared 20% In September](https://reader035.vdocuments.us/reader035/viewer/2022062823/5879838b1a28ab6c358b5f61/html5/thumbnails/7.jpg)
Leaked: The next billion-dollar iSecret